The germline sequence variant rs2736100-C in TERT associates with myeloproliferative neoplasms

Leukemia

Volumn 28, Issue 6, 2014, Pages 1371-1374

  Oddsson, A ^a   Kristinsson, S Y ^b,c   Helgason, H ^a,b   Gudbjartsson, D F ^a   Masson, G ^a   Sigurdsson, A ^a   Jonasdottir, A ^a   Steingrimsdottir, H ^c   Vidarsson, B ^c   Reykdal, S ^c   Eyjolfsson, G I ^d   Olafsson, I ^c   Onundarson, P T ^b,c   Runarsson, G ^c   Sigurdardottir, O ^e   Kong, A ^a   Rafnar, T ^a   Sulem, P ^a   Thorsteinsdottir, U ^a,b   Stefansson, K ^a,b  

^a DECODE GENETICS   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d RAM   (Iceland)

^e Akureyri Hospital   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; JANUS KINASE 2;

CONTROLLED STUDY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERMLINE SEQUENCE VARIANT; HAPLOTYPE; HUMAN; HUMAN CELL; ICELAND; INTRON; LETTER; LEUKOCYTE; MAJOR CLINICAL STUDY; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; BLOOD SAMPLING; CANCER RISK; ERYTHROCYTE COUNT; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC RISK; ICELANDER; LEUKOCYTE COUNT; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TELOMERE;

GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; TELOMERASE;

EID: 84902113651     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.48     Document Type: Letter

References (15)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International agency for research on cancer, world health organization, 2008.
2. Jones AV, Cross NC. Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol 2013; 4: 237-253.
3. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008; 111: 2785-2789.
4. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.
5. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
6. Mocellin S, Verdi D, Pooley KA, Landi MT, Egan KM, Baird DM et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: A field synopsis and meta-Analysis. J Natl Cancer Inst 2012; 104: 840-854.
7. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41: 221-227.
8. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013; 45: 422-427427e1-2.
9. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013; 45: 371-384384e1-2.
10. Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol 2013; 41: 627-634.
11. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
12. Wu XQ, Huang C, He X, Tian YY, Zhou DX, He Y et al. Feedback regulation of telomerase reverse transcriptase: New insight into the evolving field of telomerase in cancer. Cell Signal 2013; 25: 2462-2468.
13. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010; 42: 210-215.
14. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105-109.
15. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6026.